[Study of the influence of the beta-sympatholytic drug KO 1366 (Bunitrolol on lung function (author's transl)].
20 untreated outpatients suffering from chronic obstructive airway disease were tested with a new beta-sympatholytic agent, Kö 1366 (bunitrolol) or placebo in a randomized symptoms of bronchitis, but hacetylcholine inhalation was followed by severe bronchospastic hyperreactivity. The intravenous administration of 2.5 mg Kö 1366 resulted in a rapid and statistically significant (p less than 0.001) marked decrease in heart rate due to the beta-sympatholytic effect. Airway resistance, however, measured by whole-body plethysmography, was not affected. Kö 1366 can be regarded as a cardio-selective beta-sympatholytic drug in so far as i.v. administration is possible in patients with airway disease during a non-obstructive period. Moreover, should a bronchospastic reaction occur immediate control by inhalation of adrenergic or vagolytic drugs is possible.
D000328:Adult; D000402:Airway Obstruction / Q000188:drug therapy; D000403:Airway Resistance / Q000187:drug effects; D005260:Female; D006801:Humans; D007545:Isoproterenol; D008168:Lung / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000494:pharmacology*; D011674:Pulse
D011412:Propanolamines; D007545:Isoproterenol
Lungenfunktionsuntersuchungen mit dem neuen beta-Adrenolytikum Kö 1366 (Bunitrolol)